Opus Genetics, Inc. (IRD)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $390.48M
Last updated: Nov 17, 2026 at 4:15 PM ET
Opus Genetics, Inc. (IRD) Statistics
Opus Genetics (IRD) has a market cap of $390.48M and an enterprise value of $337.39M. It kept -1726.70% of revenue as net income over the last 12 months. Its share count is up 44.18% from a year earlier.
Total Valuation
Enterprise value is 13.60% below the market cap, as cash exceeds debt.
| Market Cap | $390.48M |
|---|---|
| Enterprise Value | $337.39M |
| Latest price (Nov 17, 2026) | $4.05 |
Key Dates
The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 8, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 10, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 52.1x and 10.7x. Its year-end P/S ranged from 1.9x to 9.0x from 2022 to 2025.
| P/S Ratio | 52.1x |
|---|---|
| Forward P/S | 28.7x |
| P/B Ratio | 10.7x |
Price Statistics
The stock is up 115.43% over 52 weeks and trades 9.40% below its 50-day average.
| Beta (1Y) | 1.20 |
|---|---|
| 52-Week Change | +115.43% |
| 1-Month Change | +6.02% |
| 3-Month Change | -0.49% |
| 6-Month Change | -4.93% |
| 5-Year Change | -6.85% |
| 10-Year Change | -95.42% |
| Total Return (1Y) | +115.43% |
| Total Return (3Y CAGR) | +11.39% |
| Total Return (5Y CAGR) | +2.85% |
| Return vs SPY (1Y) | +103.87% |
| Max Drawdown (1Y) | -49.22% |
| Max Drawdown (3Y) | -78.30% |
| Sharpe Ratio (1Y) | 0.99 |
| Correlation with SPY (1Y) | 0.21 |
| 50-Day Average | $4.47 |
| 200-Day Average | $4.28 |
| 52-Week Range | $1.80 to $7.07 |
| RSI (14 Days) | 49.0 |
| Average Volume (20 Days) | 1.08M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 9.65x current liabilities, and total debt is 0.93x shareholder equity.
| Current Ratio | 9.65x |
|---|---|
| Quick Ratio | 9.65x |
| Debt / Equity | 0.93x |
Returns and Efficiency
Return on invested capital is -145.13% and return on equity is -355.57% over the last 12 months.
| Return on Equity (ROE) | -355.57% |
|---|---|
| Return on Assets (ROA) | -143.40% |
| Return on Invested Capital (ROIC) | -145.13% |
| Return on Capital Employed (ROCE) | -159.74% |
| ROA (5Y Average) | -90.84% |
| Asset Turnover | 0.12x |
| Receivables Turnover | 7.74x |
Scores
IRD has an Altman Z-Score of -3.76, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -3.76 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $7.91M over the last 12 months is down 45.92% from the 12 months before.
| Revenue | $7.91M |
|---|---|
| Revenue Growth (YoY) | -45.92% |
| Gross Profit | $7.91M |
| Operating Income | -$61.54M |
| Pretax Income | -$136.65M |
| Net Income | -$136.65M |
| EBIT | -$136.52M |
| Reported EPS (TTM) | -$1.28 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 40.33% of the $95.30M in total assets.
| Cash and Equivalents | $88.97M |
|---|---|
| Total Debt | $35.88M |
| Net Cash | $53.09M |
| Net Cash Per Share | $0.52 |
| Working Capital | $85.02M |
| Shareholder Equity | $38.43M |
| Book Value Per Share | $0.38 |
| Total Assets | $95.30M |
| Total Liabilities | $56.86M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$48.55M |
|---|---|
| FCF Per Share | -$0.58 |
| Depreciation and Amortization | $62.00K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -777.66%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -777.66% |
| Pretax Margin | -1726.70% |
| Net Margin | -1726.70% |
| EBIT Margin | -1725.06% |
Growth
Revenue fell 29.11% a year over 3 years.
| Revenue Growth (3Y CAGR) | -29.11% |
|---|---|
| Book Value Per Share Growth (2Y CAGR) | -89.57% |
| Tangible Book Per Share Growth (2Y CAGR) | -89.57% |
Dividends and Yields
IRD does not pay a dividend.
| Buyback Yield | -6.02% |
|---|---|
| Shareholder Yield | -6.02% |
Stock Splits
The last split was a 1-for-4 reverse split on Nov 6, 2020.
| Last Split Date | Nov 6, 2020 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:4 |
Peer Position
Against 5 similar companies, IRD has the 3rd highest P/S.
P/S RatioPeer median 5.4x
ROICPeer median -15.40%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -88.33%
| P/S Ratio | 52.1x vs 5.4x median |
|---|---|
| ROIC | -145.13% vs -15.40% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -45.92% vs -88.33% median |
Analyst Forecast
Consensus estimates put revenue growth at -6.52% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -6.52% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About IRD
What is IRD's market cap?
Opus Genetics has a market cap of $390.48M. Its enterprise value, which adds debt and subtracts cash, is $337.39M.
How many shares of IRD are outstanding?
Opus Genetics has 101.84M shares outstanding. The count is up 44.18% from a year earlier.
Does IRD pay a dividend?
No. Opus Genetics does not pay a dividend.
How much debt does IRD have?
Opus Genetics has $35.88M of total debt and $88.97M of cash and equivalents, a net cash position of $53.09M.
IRD pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors